ClinicalTrials.gg
CompletedNCT02031640Updated Nov 9, 2021Results posted

A Safety and Efficacy Study of Beclomethasone Dipropionate Delivered Via Breath-Actuated Inhaler (BAI) or Metered-Dose Inhaler (MDI) in Participants >=12 Years Old With Persistent Asthma

A Phase 3 interventional study of Beclomethasone dipropionate and Placebo in Asthma, sponsored by Teva Branded Pharmaceutical Products R&D, Inc.. Completed at 131 sites in 4 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2021-11-09.

Sponsored by Teva Branded Pharmaceutical Products R&D, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,113
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing beclomethasone in Asthma — none open to participants now, none under way, none of them phase 3. Beclomethasone · Asthma.

Enrollment
3rd of 40
1,113 · median 67
Started
2013
with 4 others
Phase 3
20 of 40
none open now
Registered
25th of 40
by date
Lead sponsor
7 of 40
Teva Branded Pharmaceutical Products R&D, Inc.

Among the 40 studies testing beclomethasone in Asthma, this one is the 3rd largest by enrollment, is one of 5 that started in 2013, is one of 20 in phase 3, and was the 25th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 40 studies testing beclomethasone in Asthma is open now. The open studies under Asthma, anywhere →

About beclomethasone

Beclomethasone: first FDA approval 1976 (VANCERIL), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing beclomethasone in Asthma as a file.
02

Study summary

This is a Phase 3, randomized, placebo-controlled, double-blind,double-dummy, parallel-group, 12-week study in male and female patients, 12 years of age and older, with persistent asthma.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • asthma
  • breath-actuated inhaler
  • metered-dose inhaler
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Severity of disease: The patient has persistent asthma, with a (FEV1) 40%-85% of the value predicted for age, height, sex, and race as per the National Health and Nutrition Examination Survey (NHANES III) (Hankinson et al 1999) reference values at screening visit.
  • Current asthma therapy: The patient must be on a stable dose of an inhaled (ICS) of at least 440 mcg/day of fluticasone propionate or equivalent for a minimum of 4 weeks before screening visit, or any inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) combination for a minimum of 4 weeks before the prescreening visit.
  • Reversibility of disease: The patient has demonstrated at least 12% reversibility of FEV1 and at least 200 mL increase from baseline FEV1 (patients age 18 and older) within 30 minutes after 2-4 inhalations of albuterol/salbutamol hydrofluoroalkane (HFA) MDI (90 mcg ex-actuator) or equivalent at the screening visit
  • If female, the patient is currently not pregnant, breast feeding, or attempting to become pregnant. If of , has a negative serum pregnancy test and is willing to commit to using a consistent and acceptable method of .
  • Other criteria apply, please contact the investigator for more information

Exclusion criteria

Exclusion Criteria:

  • The patient has a history of life-threatening asthma, defined for this protocol as an asthma episode that required intubation and/or was associated with hypercapnea, respiratory arrest, or hypoxic seizures.
  • The patient is pregnant or lactating, or plans to become pregnant during the study period or for 30 days after the patient's last study-related visit (for eligible patients only, if applicable). Eligible female patients unwilling to employ appropriate measures to ensure that pregnancy will not occur during the study will be excluded. Any patient becoming pregnant during the study will be withdrawn from the study.
  • The patient has a known to any or any of the in the study drug or rescue medication formulation.
  • The patient currently smokes or has a smoking history of 10 pack-years or more (a pack-year is defined as smoking 1 pack of cigarettes/day for 1 year).
  • The patient has had an asthma exacerbation requiring oral corticosteroids within 30 days before the screening visit, or has had any hospitalization for asthma within 2 months before the screening visit.
  • The patient has historical or current evidence of a disease. Significant disease is defined as any disease that in the medical judgment of the investigator would put the safety of the patient at risk through participation or that could affect the efficacy or safety analysis if the disease/condition worsened during the study.
  • Other criteria apply, please contact the investigator for more information
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,113 participants (actual)

Study arms

  • Experimental
    BDP 320 mcg BAI

    Beclomethasone dipropionate (BDP) via breath-actuated inhaler (BAI) twice daily.

    Drug: Beclomethasone dipropionate · Drug: Placebo · Drug: Albuterol/salbutamol

  • Experimental
    BDP 640 mcg BAI

    Beclomethasone dipropionate (BDP) via breath-actuated inhaler (BAI) twice daily.

    Drug: Beclomethasone dipropionate · Drug: Placebo · Drug: Albuterol/salbutamol

  • Active comparator
    BDP 320 mcg MDI

    Beclomethasone dipropionate (BDP) via metered dose inhaler (MDI) twice daily.

    Drug: Beclomethasone dipropionate · Drug: Placebo · Drug: Albuterol/salbutamol

  • Active comparator
    BDP 640 mcg MDI

    Beclomethasone dipropionate (BDP) via metered dose inhaler (MDI) twice daily.

    Drug: Beclomethasone dipropionate · Drug: Placebo · Drug: Albuterol/salbutamol

  • Placebo comparator
    Placebo BAI and MDI

    Placebo breath-actuated inhaler (BAI), twice daily. Plus placebo metered dose inhaler (MDI), twice daily.

    Drug: Placebo · Drug: Albuterol/salbutamol

Interventions

  • Also known as: BDP

  • DrugPlacebo
  • DrugAlbuterol/salbutamol

    Drug page: Albuterol

    Rescue medication (albuterol/salbutamol hydrofluoroalkane (HFA) MDI \[90 mcg ex-actuator\] or equivalent) for use on an as-needed basis for the immediate relief of asthma symptoms throughout the treatment period.

    Also known as: bronchodilators

06

What researchers measure

Primary outcomes

  1. Standardized Baseline-adjusted Trough Morning Forced Expiratory Volume in 1 Second (FEV1) Area Under the Effect Curve From Time 0 to 12 Weeks (AUEC(0-12wk) )

    Trough morning FEV1 measurements were taken pre-dose and pre-rescue bronchodilator treatment for asthma. The baseline pulmonary function measurement was defined as the measurement obtained at randomization visit (Day 1). Pulmonary function measurements (including FEV1) were obtained electronically by spirometry. All pulmonary function test data were submitted to a central reading center for evaluation. The highest FEV1 value from 3 acceptable and 2 repeatable maneuvers (maximum of 5 attempts) was used. Baseline-adjusted FEV1 AUEC(0-12wk) were calculated using the trapezoidal rule. The standardized baseline-adjusted FEV1 AUEC(0-12 wk) accommodates participants who dropped out of the study. Baseline-adjusted FEV1 AUEC(0-t weeks)/t, where t =12 weeks for patients who complete the FEV1 assessment at Week 12. For participants who dropped out early, t \<12 weeks (2, 4, or 8 weeks).

    Time frame: Day 1 (baseline), Weeks 2, 4, 8, 12

Secondary outcomes

  1. Change From Baseline in Weekly Average of Daily Trough Morning Peak Expiratory Flow (PEF) Over the 12-week Treatment Period Using a Mixed Model for Repeated Measures (MMRM)

    A hand-held peak flow meter was provided to patients at the screening visit and used to determine the morning and evening PEF throughout the course of the study. Daily trough morning PEF assessments were taken pre-dose and pre-rescue bronchodilator over the 12-week treatment period. The patient recorded the highest value of 3 measurements obtained in the morning and evening in the patient diary. Baseline in trough morning PEF is defined as the average of recorded trough morning PEF assessments over the 7-day window before randomization, including the morning assessment on Day 1 before randomization. Weekly average PEF data was generated using 7-day windows based on analysis days (before the first dose of double-blind study treatment). PEF over the 12 week treatment period was performed using a mixed-model for repeated measures (MMRM) with effects due to baseline weekly average of daily trough morning PEF, sex, age, treatment, time, and time by treatment interaction.

    Time frame: Baseline: Days -6 to Day 1 (pre-randomization), Treatment: Day 2 to Week 12

  2. Change From Baseline in Weekly Average of Daily Evening Peak Expiratory Flow (PEF) Over the 12-week Treatment Period Using a Mixed Model for Repeated Measures (MMRM)

    A hand-held peak flow meter was provided to patients at the screening visit and used to determine the morning and evening PEF throughout the course of the study. The patient recorded the highest value of 3 measurements obtained in the morning and evening in the patient diary. Baseline in evening PEF is defined as the average of recorded evening PEF assessments over the 7-day window before randomization. Weekly average PEF data was generated using 7-day windows based on analysis days (after the first dose of double-blind study treatment). PEF over the 12 week treatment period was performed using a mixed-model for repeated measures (MMRM) with effects due to baseline weekly average of daily evening peak PEF, sex, age, treatment, time, and time by treatment interaction.

    Time frame: Baseline: Days -7 to Day -1, Treatment: Day 1 to Week 12

  3. Change From Baseline in the Weekly Average of Total Daily (24-hour) Use of Albuterol/Salbutamol Inhalation Aerosol (Number of Inhalations) Over Weeks 1-12 Using a Mixed Model for Repeated Measures (MMRM)

    Change from baseline in the use of rescue medication, albuterol/salbutamol, during the treatment period offers an indication of asthma control. Baseline was defined as the average of recorded daily usage of albuterol/salbutamol inhalation aerosol over the 7 days prior to the first dose of double-blind study treatment, including the morning usage at the randomization visit. Weekly average rescue medication data was generated using 7-day windows based on analysis days (after the first dose of double-blind study treatment). Weekly average over the 12 week treatment period was performed using a mixed-model for repeated measures (MMRM) with effects due to baseline value, sex, age, time, treatment, and time-by-treatment interaction.

    Time frame: Baseline: Days -6 to Day 1 (pre-randomization), Treatment: Day 1 to Week 12

  4. Change From Baseline in the Weekly Average of the Total Daily Asthma Symptom Score Over Weeks 1-12 Using a Mixed Model for Repeated Measures (MMRM)

    Asthma symptom scores are recorded in the patient's diary each morning and each evening before determining PEF and before administration of study or rescue medications. The Daytime Symptom Score (determined in the evening) has a range from 0=No symptoms during the day to 5=Symptoms so severe that I could not go to work or perform normal daily activities. The Nighttime Symptom Score (determined in the morning) has a range from 0=No symptoms during the night to 4=Symptoms so severe that I did not sleep at all. The total daily asthma symptom score is the average of the daytime and the nighttime scores (full scale is 0 - 4.5). The total daily asthma symptom score is missing if either the daytime or nighttime score is missing. Baseline was the average of recorded daily asthma symptom scores over 7 days prior to the first dose of study treatment. The weekly average was the sum of total daily asthma symptom scores over the 7 days divided by the number of non-missing assessments.

    Time frame: Days -6 to Day 1 (pre-randomization), Treatment: Day 1 to Week 12

  5. Kaplan-Meier Estimates for Time to Withdrawal From Study Treatment Due to Meeting Stopping Criteria for Worsening Asthma

    Time to withdrawal due to meeting stopping criteria is defined as number of days elapsed from the date of the first dose of double-blind study treatment to the date of withdrawal due to meeting stopping criteria. Stopping criteria are: * FEV1 as measured at the study center is below the FEV1 stability limit value calculated at RV. * Based upon review of patient diary data, the patient has experienced any of the following during any 7-day period: * 4+ days in which the highest (of 3 efforts) am PEF fall below the PEF stability limit calculated when randomized. The patient meets with the investigator who determines whether the FEV1 is consistent with worsening asthma; * 3+ days in which 12+ inhalations/day of rescue medication were used * 2+ days in which the patient experienced a nighttime asthma symptom score of more than 2 * Clinical asthma exacerbation requiring (for example) the use of systemic corticosteroids, or the emergency room or hospitalization.

    Time frame: Day 1 - Week 12

  6. Number of Participants Withdrawn From Study Due to Meeting Stopping Criteria for Worsening Asthma During the 12-Week Treatment Period

    A count of participants who were withdrawn from the study due to meeting stopping criteria. Alert criteria for individual patients with worsening asthma were designed to ensure patient safety. The investigator determined whether the patient's overall clinical picture is consistent with worsening asthma and if the patient should be withdrawn from study drug treatment (but not the study) and be placed on appropriate asthma therapy in the interest of patient safety. An example of alert criteria is: * FEV1 as measured at the study center is below the FEV1 stability limit value calculated at randomization visit (Day 1). * Other criteria as defined in the protocol.

    Time frame: Treatment period: Day 1 up to Week 12

07

Results

Posted Jan 5, 2018

Participant flow

For this study, 125 sites were activated, 115 sites screened at least 1 patient (91 centers in the United States, 10 centers in Germany, 10 centers in Hungary, and 4 centers in Poland), and 97 sites randomized at least 1 patient.

Screening Period
Participant flow — Screening Period
MilestoneConsented Patients - Standard ICS and PlaceboPlacebo BAI and MDIBDP 320 mcg BAIBDP 640 mcg BAIBDP 320 mcg MDIBDP 640 mcg MDI
Started111300000
Completed70100000
Not completed41200000
Withdrew: Adverse event100000
Withdrew: Withdrawal by subject2900000
Withdrew: Inclusion criteria not met31200000
Withdrew: Exclusion criteria met3000000
Withdrew: Lost to follow-up1400000
Withdrew: Enrollment closed2600000
Run-In Period
Participant flow — Run-In Period
MilestoneConsented Patients - Standard ICS and PlaceboPlacebo BAI and MDIBDP 320 mcg BAIBDP 640 mcg BAIBDP 320 mcg MDIBDP 640 mcg MDI
Started70100000
Completed53200000
Not completed16900000
Withdrew: Adverse event400000
Withdrew: Withdrawal by subject1700000
Withdrew: Inclusion criteria not met3800000
Withdrew: Exclusion criteria met800000
Withdrew: Randomization criteria not met8500000
Withdrew: Various administrative reasons1700000
Double-blind Treatment Period
Participant flow — Double-blind Treatment Period
MilestoneConsented Patients - Standard ICS and PlaceboPlacebo BAI and MDIBDP 320 mcg BAIBDP 640 mcg BAIBDP 320 mcg MDIBDP 640 mcg MDI
Started0106106106107107
Full analysis set0106104106106107
Completed0841009996104
Not completed02267113
Withdrew: Protocol deviation020131
Withdrew: Lack of efficacy0143251
Withdrew: Non-compliance010110
Withdrew: Adverse event000200
Withdrew: Withdrawal by subject023111
Withdrew: Lost to follow-up030010

Outcome measures

PrimaryStandardized Baseline-adjusted Trough Morning Forced Expiratory Volume in 1 Second (FEV1) Area Under the Effect Curve From Time 0 to 12 Weeks (AUEC(0-12wk) )

Trough morning FEV1 measurements were taken pre-dose and pre-rescue bronchodilator treatment for asthma. The baseline pulmonary function measurement was defined as the measurement obtained at randomization visit (Day 1). Pulmonary function measurements (including FEV1) were obtained electronically by spirometry. All pulmonary function test data were submitted to a central reading center for evaluation. The highest FEV1 value from 3 acceptable and 2 repeatable maneuvers (maximum of 5 attempts) was used. Baseline-adjusted FEV1 AUEC(0-12wk) were calculated using the trapezoidal rule. The standardized baseline-adjusted FEV1 AUEC(0-12 wk) accommodates participants who dropped out of the study. Baseline-adjusted FEV1 AUEC(0-t weeks)/t, where t =12 weeks for patients who complete the FEV1 assessment at Week 12. For participants who dropped out early, t \<12 weeks (2, 4, or 8 weeks).

Time frame:
Day 1 (baseline), Weeks 2, 4, 8, 12
Reported as:
Least squares mean · Liters
Standardized Baseline-adjusted Trough Morning Forced Expiratory Volume in 1 Second (FEV1) Area Under the Effect Curve From Time 0 to 12 Weeks (AUEC(0-12wk) )
LitersPlacebo BAI and MDIBDP 320 mcg BAIBDP 640 mcg BAIBDP 320 mcg MDIBDP 640 mcg MDI
Standardized Baseline-adjusted Trough Morning Forced Expiratory Volume in 1 Second (FEV1) Area Under the Effect Curve From Time 0 to 12 Weeks (AUEC(0-12wk) )0.056 ± 0.02190.09 ± 0.02210.101 ± 0.02210.041 ± 0.02170.096 ± 0.0216
Statistical analysis
  • Placebo BAI and MDI vs BDP 320 mcg BAI · ANCOVA · p = 0.272 · Least square mean (lsm) difference: 0.034 · 95% CI -0.027 to 0.095
  • Placebo BAI and MDI vs BDP 640 mcg BAI · ANCOVA · p = 0.1415 · Lsm difference: 0.045 · 95% CI -0.015 to 0.106
  • Placebo BAI and MDI vs BDP 320 mcg MDI · ANCOVA · p = 0.6356 · Lsm difference: -0.015 · 95% CI -0.075 to 0.046
  • Placebo BAI and MDI vs BDP 640 mcg MDI · ANCOVA · p = 0.1932 · Lsm difference: 0.04 · 95% CI -0.02 to 0.1
SecondaryChange From Baseline in Weekly Average of Daily Trough Morning Peak Expiratory Flow (PEF) Over the 12-week Treatment Period Using a Mixed Model for Repeated Measures (MMRM)

A hand-held peak flow meter was provided to patients at the screening visit and used to determine the morning and evening PEF throughout the course of the study. Daily trough morning PEF assessments were taken pre-dose and pre-rescue bronchodilator over the 12-week treatment period. The patient recorded the highest value of 3 measurements obtained in the morning and evening in the patient diary. Baseline in trough morning PEF is defined as the average of recorded trough morning PEF assessments over the 7-day window before randomization, including the morning assessment on Day 1 before randomization. Weekly average PEF data was generated using 7-day windows based on analysis days (before the first dose of double-blind study treatment). PEF over the 12 week treatment period was performed using a mixed-model for repeated measures (MMRM) with effects due to baseline weekly average of daily trough morning PEF, sex, age, treatment, time, and time by treatment interaction.

Time frame:
Baseline: Days -6 to Day 1 (pre-randomization), Treatment: Day 2 to Week 12
Reported as:
Least squares mean · Liters/minute
Change From Baseline in Weekly Average of Daily Trough Morning Peak Expiratory Flow (PEF) Over the 12-week Treatment Period Using a Mixed Model for Repeated Measures (MMRM)
Liters/minutePlacebo BAI and MDIBDP 320 mcg BAIBDP 640 mcg BAIBDP 320 mcg MDIBDP 640 mcg MDI
Change From Baseline in Weekly Average of Daily Trough Morning Peak Expiratory Flow (PEF) Over the 12-week Treatment Period Using a Mixed Model for Repeated Measures (MMRM)-5.524 ± 2.59445.092 ± 2.56252.895 ± 2.5590.480 ± 2.5586.988 ± 2.5298
Statistical analysis
  • Placebo BAI and MDI vs BDP 320 mcg BAI · Mixed Model for repeated measures · p = 0.0036 · Lsm difference: 10.616 · 95% CI 3.489 to 17.744
  • Placebo BAI and MDI vs BDP 640 mcg BAI · Mixed Model for repeated measures · p = 0.0204 · Lsm difference: 8.419 · 95% CI 1.309 to 15.53
  • Placebo BAI and MDI vs BDP 320 mcg MDI · Mixed Model for repeated measures · p = 0.0984 · Lsm difference: 6.004 · 95% CI -1.121 to 13.129
  • Placebo BAI and MDI vs BDP 640 mcg BAI · Mixed Model for repeated measures · p = 0.0006 · Lsm difference: 12.512 · 95% CI 5.435 to 19.589
SecondaryChange From Baseline in Weekly Average of Daily Evening Peak Expiratory Flow (PEF) Over the 12-week Treatment Period Using a Mixed Model for Repeated Measures (MMRM)

A hand-held peak flow meter was provided to patients at the screening visit and used to determine the morning and evening PEF throughout the course of the study. The patient recorded the highest value of 3 measurements obtained in the morning and evening in the patient diary. Baseline in evening PEF is defined as the average of recorded evening PEF assessments over the 7-day window before randomization. Weekly average PEF data was generated using 7-day windows based on analysis days (after the first dose of double-blind study treatment). PEF over the 12 week treatment period was performed using a mixed-model for repeated measures (MMRM) with effects due to baseline weekly average of daily evening peak PEF, sex, age, treatment, time, and time by treatment interaction.

Time frame:
Baseline: Days -7 to Day -1, Treatment: Day 1 to Week 12
Reported as:
Least squares mean · Liters/minute
Change From Baseline in Weekly Average of Daily Evening Peak Expiratory Flow (PEF) Over the 12-week Treatment Period Using a Mixed Model for Repeated Measures (MMRM)
Liters/minutePlacebo BAI and MDIBDP 320 mcg BAIBDP 640 mcg BAIBDP 320 mcg MDIBDP 640 mcg MDI
Change From Baseline in Weekly Average of Daily Evening Peak Expiratory Flow (PEF) Over the 12-week Treatment Period Using a Mixed Model for Repeated Measures (MMRM)-4.708 ± 2.65034.439 ± 2.61994.462 ± 2.6092-0.62 ± 2.61455.594 ± 2.5848
Statistical analysis
  • Placebo BAI and MDI vs BDP 320 mcg BAI · Mixed Model for repeated measures · p = 0.0139 · Lsm difference: 9.147 · 95% CI 1.866 to 16.429
  • Placebo BAI and MDI vs BDP 640 mcg BAI · Mixed Model for repeated measures · p = 0.0133 · Lsm difference: 9.17 · 95% CI 1.914 to 16.425
  • Placebo BAI and MDI vs BDP 320 mcg MDI · Mixed Model for repeated measures · p = 0.2704 · Lsm difference: 4.088 · 95% CI -3.191 to 11.367
  • Placebo BAI and MDI vs BDP 640 mcg MDI · Mixed Model for repeated measures · p = 0.0053 · Lsm difference: 10.301 · 95% CI 3.073 to 17.53
SecondaryChange From Baseline in the Weekly Average of Total Daily (24-hour) Use of Albuterol/Salbutamol Inhalation Aerosol (Number of Inhalations) Over Weeks 1-12 Using a Mixed Model for Repeated Measures (MMRM)

Change from baseline in the use of rescue medication, albuterol/salbutamol, during the treatment period offers an indication of asthma control. Baseline was defined as the average of recorded daily usage of albuterol/salbutamol inhalation aerosol over the 7 days prior to the first dose of double-blind study treatment, including the morning usage at the randomization visit. Weekly average rescue medication data was generated using 7-day windows based on analysis days (after the first dose of double-blind study treatment). Weekly average over the 12 week treatment period was performed using a mixed-model for repeated measures (MMRM) with effects due to baseline value, sex, age, time, treatment, and time-by-treatment interaction.

Time frame:
Baseline: Days -6 to Day 1 (pre-randomization), Treatment: Day 1 to Week 12
Reported as:
Least squares mean · number of inhalations
Change From Baseline in the Weekly Average of Total Daily (24-hour) Use of Albuterol/Salbutamol Inhalation Aerosol (Number of Inhalations) Over Weeks 1-12 Using a Mixed Model for Repeated Measures (MMRM)
number of inhalationsPlacebo BAI and MDIBDP 320 mcg BAIBDP 640 mcg BAIBDP 320 mcg MDIBDP 640 mcg MDI
Change From Baseline in the Weekly Average of Total Daily (24-hour) Use of Albuterol/Salbutamol Inhalation Aerosol (Number of Inhalations) Over Weeks 1-12 Using a Mixed Model for Repeated Measures (MMRM)0.478 ± 0.1232-0.226 ± 0.1235-0.213 ± 0.1221-0.173 ± 0.1246-0.323 ± 0.1206
Statistical analysis
  • Placebo BAI and MDI vs BDP 320 mcg BAI · Mixed Model for repeated measures · p = <0.0001 · Lsm difference: -0.703 · 95% CI -1.044 to -0.363
  • Placebo BAI and MDI vs BDP 640 mcg BAI · Mixed Model for repeated measures · p = <0.0001 · Lsm difference: -0.691 · 95% CI -1.029 to -0.352
  • Placebo BAI and MDI vs BDP 320 mcg MDI · Mixed Model for repeated measures · p = 0.0002 · Lsm difference: -0.651 · 95% CI -0.994 to -0.309
  • Placebo BAI and MDI vs BDP 640 mcg MDI · Mixed Model for repeated measures · p = <0.0001 · Lsm difference: -0.801 · 95% CI -1.138 to -0.464
SecondaryChange From Baseline in the Weekly Average of the Total Daily Asthma Symptom Score Over Weeks 1-12 Using a Mixed Model for Repeated Measures (MMRM)

Asthma symptom scores are recorded in the patient's diary each morning and each evening before determining PEF and before administration of study or rescue medications. The Daytime Symptom Score (determined in the evening) has a range from 0=No symptoms during the day to 5=Symptoms so severe that I could not go to work or perform normal daily activities. The Nighttime Symptom Score (determined in the morning) has a range from 0=No symptoms during the night to 4=Symptoms so severe that I did not sleep at all. The total daily asthma symptom score is the average of the daytime and the nighttime scores (full scale is 0 - 4.5). The total daily asthma symptom score is missing if either the daytime or nighttime score is missing. Baseline was the average of recorded daily asthma symptom scores over 7 days prior to the first dose of study treatment. The weekly average was the sum of total daily asthma symptom scores over the 7 days divided by the number of non-missing assessments.

Time frame:
Days -6 to Day 1 (pre-randomization), Treatment: Day 1 to Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in the Weekly Average of the Total Daily Asthma Symptom Score Over Weeks 1-12 Using a Mixed Model for Repeated Measures (MMRM)
units on a scalePlacebo BAI and MDIBDP 320 mcg BAIBDP 640 mcg BAIBDP 320 mcg MDIBDP 640 mcg MDI
Change From Baseline in the Weekly Average of the Total Daily Asthma Symptom Score Over Weeks 1-12 Using a Mixed Model for Repeated Measures (MMRM)-0.058 ± 0.0425-0.207 ± 0.0417-0.159 ± 0.0415-0.247 ± 0.0417-0.274 ± 0.0411
Statistical analysis
  • Placebo BAI and MDI vs BDP 320 mcg BAI · Mixed Models Analysis · p = 0.0119 · Mean difference (final values): -0.149 · 95% CI -0.265 to -0.033
  • Placebo BAI and MDI vs BDP 640 mcg BAI · Mixed Models Analysis · p = 0.0854 · Mean difference (final values): -0.102 · 95% CI -0.217 to 0.014
  • Placebo BAI and MDI vs BDP 320 mcg MDI · Mixed Models Analysis · p = 0.0016 · Mean difference (final values): -0.189 · 95% CI -0.306 to -0.072
  • Placebo BAI and MDI vs BDP 640 mcg MDI · Mixed Models Analysis · p = 0.0003 · Mean difference (final values): -0.216 · 95% CI -0.332 to -0.101
SecondaryKaplan-Meier Estimates for Time to Withdrawal From Study Treatment Due to Meeting Stopping Criteria for Worsening Asthma

Time to withdrawal due to meeting stopping criteria is defined as number of days elapsed from the date of the first dose of double-blind study treatment to the date of withdrawal due to meeting stopping criteria. Stopping criteria are: * FEV1 as measured at the study center is below the FEV1 stability limit value calculated at RV. * Based upon review of patient diary data, the patient has experienced any of the following during any 7-day period: * 4+ days in which the highest (of 3 efforts) am PEF fall below the PEF stability limit calculated when randomized. The patient meets with the investigator who determines whether the FEV1 is consistent with worsening asthma; * 3+ days in which 12+ inhalations/day of rescue medication were used * 2+ days in which the patient experienced a nighttime asthma symptom score of more than 2 * Clinical asthma exacerbation requiring (for example) the use of systemic corticosteroids, or the emergency room or hospitalization.

Time frame:
Day 1 - Week 12
Reported as:
Median · days
Kaplan-Meier Estimates for Time to Withdrawal From Study Treatment Due to Meeting Stopping Criteria for Worsening Asthma
daysPlacebo BAI or MDIBDP 320 mcg BAIBDP 640 mcg BAIBDP 320 mcg MDIBDP 640 mcg MDI
Kaplan-Meier Estimates for Time to Withdrawal From Study Treatment Due to Meeting Stopping Criteria for Worsening AsthmaNA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)NA (NA to NA)
SecondaryNumber of Participants Withdrawn From Study Due to Meeting Stopping Criteria for Worsening Asthma During the 12-Week Treatment Period

A count of participants who were withdrawn from the study due to meeting stopping criteria. Alert criteria for individual patients with worsening asthma were designed to ensure patient safety. The investigator determined whether the patient's overall clinical picture is consistent with worsening asthma and if the patient should be withdrawn from study drug treatment (but not the study) and be placed on appropriate asthma therapy in the interest of patient safety. An example of alert criteria is: * FEV1 as measured at the study center is below the FEV1 stability limit value calculated at randomization visit (Day 1). * Other criteria as defined in the protocol.

Time frame:
Treatment period: Day 1 up to Week 12
Reported as:
Count of participants · Participants
Number of Participants Withdrawn From Study Due to Meeting Stopping Criteria for Worsening Asthma During the 12-Week Treatment Period
ParticipantsPlacebo BAI or MDIBDP 320 mcg BAIBDP 640 mcg BAIBDP 320 mcg MDIBDP 640 mcg MDI
Number of Participants Withdrawn From Study Due to Meeting Stopping Criteria for Worsening Asthma During the 12-Week Treatment Period153351

Adverse events

Collected over - Run-In Period: Days -21 to Day 1 - Double-blind Treatment Period: Day 1 to Week 12. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BDP 320 mcg BAI0/106 (0%)1/106 (0.9%)9/106 (8.5%)
BAI 640 mcg/Day0/106 (0%)1/106 (0.9%)11/106 (10.4%)
MDI 320 mcg/Day0/107 (0%)1/107 (0.9%)9/107 (8.4%)
MDI 640 mcg/Day0/107 (0%)2/107 (1.9%)12/107 (11.2%)
Placebo BAI and MDI0/106 (0%)0/106 (0%)2/106 (1.9%)
Run-in Period Experience for Randomized Participants0/532 (0%)1/532 (0.2%)8/532 (1.5%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventBDP 320 mcg BAIBAI 640 mcg/DayMDI 320 mcg/DayMDI 640 mcg/DayPlacebo BAI and MDIRun-in Period Experience for Randomized Participants
GastroenteritisInfections and infestations1/1060/1060/1070/1070/1060/532
HypokalaemiaMetabolism and nutrition disorders1/1060/1060/1070/1070/1060/532
Renal failure acuteRenal and urinary disorders1/1060/1060/1070/1070/1060/532
AsthmaRespiratory, thoracic and mediastinal disorders0/1061/1060/1070/1070/1060/532
Abdominal painGastrointestinal disorders0/1060/1061/1070/1070/1060/532
Diverticular perforationGastrointestinal disorders0/1060/1060/1071/1070/1060/532
Gastric disorderGastrointestinal disorders0/1060/1061/1070/1070/1060/532
Pancreatitis acuteGastrointestinal disorders0/1060/1061/1070/1070/1060/532
CholelithiasisHepatobiliary disorders0/1060/1061/1070/1070/1060/532
Pharyngeal abscessInfections and infestations0/1060/1060/1071/1070/1060/532
Most frequent other events
Most frequent other events
EventBDP 320 mcg BAIBAI 640 mcg/DayMDI 320 mcg/DayMDI 640 mcg/DayPlacebo BAI and MDIRun-in Period Experience for Randomized Participants
Oral candidiasisInfections and infestations5/10610/1063/1079/1070/1067/532
Upper respiratory tract infectionInfections and infestations4/1061/1067/1074/1072/1061/532

Baseline characteristics

Patients administered 4 inhalations from each of the 2 devices twice daily as per the double dummy study design: 1 treatment device or placebo and 1 placebo device for a total of 8 inhalations each time.

Age, Categorical
Age, Categorical(Participants)Placebo BAI and MDIBDP 320 mcg BAIBDP 640 mcg BAIBDP 320 mcg MDIBDP 640 mcg MDITotal
<=18 years4574626
Between 18 and 65 years9486929392457
>=65 years815710949
Sex: Female, Male
Sex: Female, Male(Participants)Placebo BAI and MDIBDP 320 mcg BAIBDP 640 mcg BAIBDP 320 mcg MDIBDP 640 mcg MDITotal
Female6869676566335
Male3837394241197
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo BAI and MDIBDP 320 mcg BAIBDP 640 mcg BAIBDP 320 mcg MDIBDP 640 mcg MDITotal
American Indian or Alaska Native000000
Asian000000
Native Hawaiian or Other Pacific Islander6352218
Black or African American271814162499
White7385878981415
More than one race000000
Unknown or Not Reported000000
08

Study locations

131 sites
  • Teva Investigational Site 10851
    Costa Mesa, California, United States
  • Teva Investigational Site 10849
    Huntington Beach, California, United States
  • Teva Investigational Site 10872
    Huntington Beach, California, United States
  • Teva Investigational Site 10833
    Long Beach, California, United States
  • Teva Investigational Site 10861
    Los Angeles, California, United States
  • Teva Investigational Site 10798
    Mission Viejo, California, United States
  • Teva Investigational Site 10806
    Orange, California, United States
  • Teva Investigational Site 10828
    Orange, California, United States
  • Teva Investigational Site 10860
    Paramount, California, United States
  • Teva Investigational Site 10813
    Rancho Mirage, California, United States
  • Teva Investigational Site 10843
    Riverside, California, United States
  • Teva Investigational Site 10857
    Rolling Hills Estates, California, United States
  • Teva Investigational Site 10847
    San Diego, California, United States
  • Teva Investigational Site 10871
    San Diego, California, United States
  • Teva Investigational Site 10876
    San Jose, California, United States
  • Teva Investigational Site 12270
    Walnut Creek, California, United States
  • Teva Investigational Site 12266
    Centennial, Colorado, United States
  • Teva Investigational Site 10838
    Colorado Springs, Colorado, United States
  • Teva Investigational Site 10844
    Denver, Colorado, United States
  • Teva Investigational Site 10799
    Wheat Ridge, Colorado, United States
  • Teva Investigational Site 10826
    Aventura, Florida, United States
  • Teva Investigational Site 10877
    Clearwater, Florida, United States
  • Teva Investigational Site 10816
    Edgewater, Florida, United States
  • Teva Investigational Site 12268
    Melbourne, Florida, United States
  • Teva Investigational Site 10807
    Miami, Florida, United States
  • Teva Investigational Site 10840
    Miami, Florida, United States
  • Teva Investigational Site 12269
    Miami, Florida, United States
  • Teva Investigational Site 10875
    Sarasota, Florida, United States
  • Teva Investigational Site 10855
    Tallahassee, Florida, United States
  • Teva Investigational Site 10864
    Tampa, Florida, United States
  • Teva Investigational Site 10858
    Albany, Georgia, United States
  • Teva Investigational Site 10862
    Lawrenceville, Georgia, United States
  • Teva Investigational Site 10848
    Savannah, Georgia, United States
  • Teva Investigational Site 10829
    River Forest, Illinois, United States
  • Teva Investigational Site 10809
    Indianapolis, Indiana, United States
  • Teva Investigational Site 10795
    Iowa City, Iowa, United States
  • Teva Investigational Site 10870
    Owensboro, Kentucky, United States
  • Teva Investigational Site 10832
    Baltimore, Maryland, United States
  • Teva Investigational Site 10850
    Bethesda, Maryland, United States
  • Teva Investigational Site 10873
    Wheaton, Maryland, United States
  • Teva Investigational Site 12272
    White Marsh, Maryland, United States
  • Teva Investigational Site 10834
    North Dartmouth, Massachusetts, United States
  • Teva Investigational Site 10815
    Minneapolis, Minnesota, United States
  • Teva Investigational Site 10821
    Minneapolis, Minnesota, United States
  • Teva Investigational Site 10869
    Columbia, Missouri, United States
  • Teva Investigational Site 10868
    Rolla, Missouri, United States
  • Teva Investigational Site 10867
    Saint Louis, Missouri, United States
  • Teva Investigational Site 12271
    Saint Louis, Missouri, United States
  • Teva Investigational Site 10827
    Warrensburg, Missouri, United States
  • Teva Investigational Site 12261
    Missoula, Montana, United States
  • Teva Investigational Site 10794
    Bellevue, Nebraska, United States
  • Teva Investigational Site 10814
    Bellevue, Nebraska, United States
  • Teva Investigational Site 10846
    Brick, New Jersey, United States
  • Teva Investigational Site 10817
    Marlton, New Jersey, United States
  • Teva Investigational Site 10856
    Ocean City, New Jersey, United States
  • Teva Investigational Site 10845
    Skillman, New Jersey, United States
  • Teva Investigational Site 10801
    Rochester, New York, United States
  • Teva Investigational Site 10842
    Canton, Ohio, United States
  • Teva Investigational Site 10792
    Cincinnati, Ohio, United States
  • Teva Investigational Site 10811
    Cincinnati, Ohio, United States
  • Teva Investigational Site 10874
    Sylvania, Ohio, United States
  • Teva Investigational Site 12265
    Toledo, Ohio, United States
  • Teva Investigational Site 10800
    Oklahoma City, Oklahoma, United States
  • Teva Investigational Site 10853
    Oklahoma City, Oklahoma, United States
  • Teva Investigational Site 10865
    Oklahoma City, Oklahoma, United States
  • Teva Investigational Site 12796
    Oklahoma City, Oklahoma, United States
  • Teva Investigational Site 10818
    Tulsa, Oklahoma, United States
  • Teva Investigational Site 10822
    Eugene, Oregon, United States
  • Teva Investigational Site 10791
    Lake Oswego, Oregon, United States
  • Teva Investigational Site 10824
    Medford, Oregon, United States
  • Teva Investigational Site 10835
    Portland, Oregon, United States
  • Teva Investigational Site 10859
    Philadelphia, Pennsylvania, United States
  • Teva Investigational Site 12795
    Warwick, Rhode Island, United States
  • Teva Investigational Site 10837
    North Charleston, South Carolina, United States
  • Teva Investigational Site 12262
    Orangeburg, South Carolina, United States
  • Teva Investigational Site 10803
    Knoxville, Tennessee, United States
  • Teva Investigational Site 10820
    Austin, Texas, United States
  • Teva Investigational Site 10808
    Boerne, Texas, United States
  • Teva Investigational Site 10830
    Dallas, Texas, United States
  • Teva Investigational Site 10831
    El Paso, Texas, United States
  • Teva Investigational Site 10878
    Live Oak, Texas, United States
  • Teva Investigational Site 10810
    Plano, Texas, United States
  • Teva Investigational Site 10797
    San Antonio, Texas, United States
  • Teva Investigational Site 10812
    San Antonio, Texas, United States
  • Teva Investigational Site 10793
    Sugar Land, Texas, United States
  • Teva Investigational Site 10790
    Waco, Texas, United States
  • Teva Investigational Site 10823
    South Burlington, Vermont, United States
  • Teva Investigational Site 10796
    Richmond, Virginia, United States
  • Teva Investigational Site 10854
    Richmond, Virginia, United States
  • Teva Investigational Site 10805
    Bellingham, Washington, United States
  • Teva Investigational Site 10866
    Seattle, Washington, United States
  • Teva Investigational Site 12264
    Tacoma, Washington, United States
  • Teva Investigational Site 10863
    Greenfield, Wisconsin, United States
  • Teva Investigational Site 10836
    Madison, Wisconsin, United States
  • Teva Investigational Site 32326
    Berlin, Germany
  • Teva Investigational Site 32332
    Berlin, Germany
  • Teva Investigational Site 32334
    Berlin, Germany
  • Teva Investigational Site 32331
    Frankfurt, Germany
  • Teva Investigational Site 32335
    Gelnhausen, Germany
  • Teva Investigational Site 32329
    Leipzig, Germany

Showing the first 100 of 131 sites across 4 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Amar NJ, Moss MH, Kerwin EM, Li J, Small CJ. Safety and efficacy of beclomethasone dipropionate delivered by breath-actuated or metered-dose inhaler for persistent asthma. Allergy Asthma Proc. 2016 Sep;37(5):359-69. doi: 10.2500/aap.2016.37.3983. Epub 2016 Aug 9. PubMed 27510595 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2013, a primary completion of Nov 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2018, 3 years 2 months after primary completion. A results delay was requested in May 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2014
First posted
Jan 9, 2014
Start
Dec 2013
Primary completionActual
Nov 2014
CompletionActual
Dec 2014
Results delay requested
May 21, 2015
Results first posted
Jan 5, 2018
Last update
Nov 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02031640
Responsible party
Sponsor
First posted
Jan 9, 2014
Start date
Dec 2013
Primary completion
Nov 2014
Completion
Dec 2014
Results posted
Jan 5, 2018
Last update
Nov 9, 2021

Study contacts

Teva Medical Expert, MD
study director · Teva Branded Pharmaceutical Products R&D, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Beclomethasone

Start the discussion